A clinical comparison between dedifferentiated low-grade osteosarcoma and conventional osteosarcoma

Area of Science:

• Orthopedic Oncology
• Molecular Pathology
• Skeletal Tumors

Background:

• Dedifferentiated low-grade osteosarcoma (DLOS) is a rare subtype of osteosarcoma.
• Accurate diagnosis and understanding of DLOS behavior are crucial for effective treatment.

Purpose of the Study:

• To define the clinical behavior, prognosis, and optimal treatment strategies for DLOS.
• To clarify the diagnostic criteria for DLOS using molecular pathology.

Main Methods:

• Retrospective review of 13 DLOS patients diagnosed via histological and molecular criteria (MDM2/CDK4 immunohistochemistry and MDM2 amplification).
• Comparison of DLOS patients with 51 age-matched conventional osteosarcoma (COS) patients.
• Analysis of clinicopathological features, treatment response, and survival rates.

Main Results:

• Five-year overall survival rates were 85.7% for DLOS and 77.1% for COS (p=0.728).
• Five-year progression-free survival rates were 57.7% for DLOS and 44.9% for COS (p=0.368).
• DLOS demonstrated a poor response to standard chemotherapy, with 8 out of 9 cases showing <50% necrosis post-chemotherapy.

Conclusions:

• DLOS, strictly defined by histological and molecular markers, exhibits a poorer response to standard chemotherapy compared to COS.
• Despite differential treatment response, the overall clinical outcomes for DLOS and COS are not significantly different.